Alexander O. Schuth, M.D., is a distinguished medical professional and executive who currently serves as the Chief Operating and Financial Officer and Secretary at Denali Therapeutics Inc. Dr. Schuth brings a wealth of experience to his role, having spent over two decades in the biopharmaceutical industry. He joined Denali in 2015 and has been instrumental in guiding the company's strategic direction and financial operations. Prior to Denali, Dr. Schuth held significant positions at leading companies such as Genentech and Third Rock Ventures, where he honed his skills in operational management and corporate strategy. At Genentech, Dr. Schuth served as the Vice President of Business Development, where he was responsible for forging key partnerships and driving the company's growth through strategic alliances. His tenure at Genentech was marked by several successful collaborations that enhanced the company's portfolio and market presence. Before that, he worked at Third Rock Ventures, a venture capital firm focused on launching and supporting innovative biotechnology companies. His role there involved identifying promising investment opportunities and providing strategic guidance to portfolio companies, leveraging his deep understanding of the industry. In his current position at Denali Therapeutics, Dr. Schuth oversees the company's operational and financial strategies, playing a crucial role in its mission to develop transformative therapies for neurodegenerative diseases. His leadership has been pivotal in navigating the complex landscape of drug development and ensuring the company's sustainable growth. Dr. Schuth's dual expertise in medicine and finance, combined with his strategic vision, makes him a vital asset to Denali as it continues to advance its pipeline and bring new treatments to patients in need.